Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0000950170-25-110775

Chief R&D Officer sold 725 shares at $26.59 ($19,278)

From the SEC's structured data for this filing

Trades in this filing

Zalevsky Jonathan · Chief R&D Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2025-08-19 Sale : show line 1 in the form −725 $26.59 $19,278 19,668 D
Open-market sales · 725 sh · avg $26.59 · $19,278

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2025-08-19 Grant or award : show line 2 in the form Stock Option +16,666 16,666 D
Loading xslF345X05/ownership.xml…